[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20054889L - Optimalisert uttrykking av HPV 31 LI i gjaer - Google Patents

Optimalisert uttrykking av HPV 31 LI i gjaer

Info

Publication number
NO20054889L
NO20054889L NO20054889A NO20054889A NO20054889L NO 20054889 L NO20054889 L NO 20054889L NO 20054889 A NO20054889 A NO 20054889A NO 20054889 A NO20054889 A NO 20054889A NO 20054889 L NO20054889 L NO 20054889L
Authority
NO
Norway
Prior art keywords
polynucleotides
hpv31
present
prepare
hpv
Prior art date
Application number
NO20054889A
Other languages
English (en)
Other versions
NO341527B1 (no
NO20054889D0 (no
Inventor
Kathrin Ute Jansen
Henry Z Markus
Loren D Schultz
Michael P Neeper
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20054889D0 publication Critical patent/NO20054889D0/no
Publication of NO20054889L publication Critical patent/NO20054889L/no
Publication of NO341527B1 publication Critical patent/NO341527B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Syntetiske DNA-molekyler som koder for HPV31-Ll-proteinet blir tilveiebrakt.Spesifikt tilveiebringer foreliggende oppfinnelse polynukleotider som koder for HPV31-Ll-proteinet der nevnte polynukleotider er frie for interne transkripsjonstermineringssignaler som blir gjenkjent av gjær. Også tilveiebrakt blir syntetiske nukleotider som koder for HPV31-LI der polynukleotidene er blitt kodonoptimalisert for høynivåuttrykking i en gjærcelle De syntetiske molekylene kan benyttes til å fremstille HPV31-viruslignende partikler (VLPer) og for å fremstille vaksiner og farmasøytiske preparater som omfatter HPV31-VLPene. Vaksinen ifølge foreliggende oppfinnelse tilveiebringer effektiv immunprofylakse mot papillomavirusinfeksjon via nøytraliserende antistoff og cellemediert immunitet.
NO20054889A 2003-03-24 2005-10-21 Nukleinsyremolekyl som koder for optimalisert HPV31-L1-protein ekspresjon i gjær, vektor og vertscelle, fremgangsmåte for fremstilling av HPV31 L1 virus-lignende partikler (VPLer), samt fremgangsmåte for fremstilling av en vaksine for behandling eller forebygging av HPV-infeksjon. NO341527B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45717203P 2003-03-24 2003-03-24
PCT/US2004/008677 WO2004084831A2 (en) 2003-03-24 2004-03-19 Optimized expression of hpv 31 l1 in yeast

Publications (3)

Publication Number Publication Date
NO20054889D0 NO20054889D0 (no) 2005-10-21
NO20054889L true NO20054889L (no) 2005-12-19
NO341527B1 NO341527B1 (no) 2017-12-04

Family

ID=33098208

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20054889A NO341527B1 (no) 2003-03-24 2005-10-21 Nukleinsyremolekyl som koder for optimalisert HPV31-L1-protein ekspresjon i gjær, vektor og vertscelle, fremgangsmåte for fremstilling av HPV31 L1 virus-lignende partikler (VPLer), samt fremgangsmåte for fremstilling av en vaksine for behandling eller forebygging av HPV-infeksjon.
NO2018010C NO2018010I1 (no) 2003-03-24 2018-03-27 HPV 31 L1 protein
NO2022053C NO2022053I1 (no) 2003-03-24 2022-11-30 HPV 31L1 protein - forlenget SPC

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2018010C NO2018010I1 (no) 2003-03-24 2018-03-27 HPV 31 L1 protein
NO2022053C NO2022053I1 (no) 2003-03-24 2022-11-30 HPV 31L1 protein - forlenget SPC

Country Status (22)

Country Link
US (2) US7276243B2 (no)
EP (1) EP1608767B1 (no)
JP (1) JP4505452B2 (no)
KR (1) KR101080628B1 (no)
CN (1) CN100506999C (no)
AT (1) ATE546529T1 (no)
AU (1) AU2004224335B2 (no)
BR (1) BRPI0408639B8 (no)
CA (1) CA2519112C (no)
EC (1) ECSP056032A (no)
ES (1) ES2381964T3 (no)
FR (1) FR15C0079I2 (no)
HK (1) HK1090953A1 (no)
IL (1) IL171067A (no)
IS (1) IS2859B (no)
MX (1) MXPA05010285A (no)
NL (1) NL300772I2 (no)
NO (3) NO341527B1 (no)
NZ (1) NZ542246A (no)
RU (1) RU2356943C2 (no)
WO (1) WO2004084831A2 (no)
ZA (1) ZA200507178B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
NZ549898A (en) * 2004-03-24 2009-06-26 Merck & Co Inc Optimized expression of HPV 52 L1 in yeast
WO2005123762A2 (en) * 2004-06-18 2005-12-29 Indian Immunologicals Ltd Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16
JP2006262846A (ja) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk 酵母による２−デオキシ−シロ−イノソースの合成および精製する方法並びに得られた２−デオキシ−シロ−イノソース
US20100203496A1 (en) * 2005-04-28 2010-08-12 Taddeo Frank J Fluorescent Multiplex HPV PCR Assays
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
US8101342B2 (en) * 2006-08-28 2012-01-24 Sungkyunkwan University Foundation For Corporate Collaboration DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
CN101113417B (zh) * 2007-06-22 2011-04-27 山东大学 Hpv基因酵母体外翻译系统的建立
EP2479186B1 (en) * 2007-11-23 2015-08-12 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
US20110201086A1 (en) 2010-02-12 2011-08-18 Otsuka Pharmaceutical Co., Ltd. Method for producing recombinant virus
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
WO2012177970A1 (en) 2011-06-24 2012-12-27 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361377B (zh) * 2012-03-28 2017-12-05 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv6 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104164373B (zh) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv68l1蛋白的方法
CN112280793B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
RU2546243C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
US9951344B2 (en) * 2014-10-10 2018-04-24 Board Of Regents, The University Of Texas System Exogenous terminators for controlling fungal gene expression
KR101825996B1 (ko) * 2014-12-26 2018-02-09 아이진 주식회사 인유두종 바이러스의 바이러스 유사 입자 제조방법
CN106148359A (zh) * 2015-03-30 2016-11-23 上海泽润生物科技有限公司 重组人乳头瘤病毒33亚型蛋白表达
CN106701797B (zh) * 2015-08-12 2021-06-15 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106831961B (zh) 2015-12-04 2019-11-05 厦门大学 一种人乳头瘤病毒58型l1蛋白的突变体
CN114127096B (zh) * 2019-07-19 2024-04-05 神州细胞工程有限公司 嵌合的人乳头瘤病毒31型l1蛋白
JP2023516904A (ja) 2020-02-14 2023-04-21 メルク・シャープ・アンド・ドーム・エルエルシー Ｈｐｖワクチン
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
EP4380615A1 (en) 2021-08-06 2024-06-12 Merck Sharp & Dohme LLC Hpv vaccine
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法
WO2024183665A1 (zh) * 2023-03-07 2024-09-12 北京康乐卫士生物技术股份有限公司 人乳头瘤病毒疫苗及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
DK0969862T3 (da) 1997-02-07 2007-02-12 Merck & Co Inc Syntetisk HIV gag-gener
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
FR2768748B1 (fr) * 1997-09-24 2001-06-08 Rhone Poulenc Agrochimie Recodage de sequences d'adn permettant leur expression dans les levures et levures transformees obtenues
EP1105157B1 (en) 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
DE60016765T2 (de) * 1999-08-25 2005-11-24 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
DK1301614T3 (da) 2000-07-21 2007-04-02 Glaxo Group Ltd Codon-optimerede papillomavirus-sekvenser
WO2002008495A1 (fr) 2000-07-26 2002-01-31 Shinko Pantec Co., Ltd. Systeme d'alimentation d'hydrogene/oxygene
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Also Published As

Publication number Publication date
CN100506999C (zh) 2009-07-01
WO2004084831A2 (en) 2004-10-07
EP1608767B1 (en) 2012-02-22
IS2859B (is) 2013-12-15
ECSP056032A (es) 2006-01-27
RU2005132603A (ru) 2006-04-27
ES2381964T3 (es) 2012-06-04
HK1090953A1 (en) 2007-01-05
BRPI0408639B1 (pt) 2020-08-18
EP1608767A2 (en) 2005-12-28
FR15C0079I2 (fr) 2016-11-25
NL300772I1 (no) 2015-12-29
AU2004224335A1 (en) 2004-10-07
JP4505452B2 (ja) 2010-07-21
IL171067A (en) 2011-11-30
JP2006523099A (ja) 2006-10-12
NZ542246A (en) 2007-12-21
BRPI0408639B8 (pt) 2021-05-25
US20060177817A1 (en) 2006-08-10
EP1608767A4 (en) 2006-08-30
NO341527B1 (no) 2017-12-04
NL300772I2 (no) 2015-12-29
NO20054889D0 (no) 2005-10-21
ATE546529T1 (de) 2012-03-15
KR101080628B1 (ko) 2011-11-08
CN1761759A (zh) 2006-04-19
NO2018010I1 (no) 2018-03-27
US7276243B2 (en) 2007-10-02
CA2519112C (en) 2012-09-11
WO2004084831A3 (en) 2004-11-11
MXPA05010285A (es) 2005-11-17
KR20050119141A (ko) 2005-12-20
RU2356943C2 (ru) 2009-05-27
BRPI0408639A (pt) 2006-03-28
IS8019A (is) 2005-09-12
NO2022053I1 (no) 2022-11-30
ZA200507178B (en) 2006-08-30
AU2004224335B2 (en) 2010-01-28
US7482428B2 (en) 2009-01-27
US20080166371A1 (en) 2008-07-10
FR15C0079I1 (no) 2016-08-01
CA2519112A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
NO20054889L (no) Optimalisert uttrykking av HPV 31 LI i gjaer
NO20064815L (no) Optimalisert uttrykking av HPV 52-L1 i gjaer
NO20061876L (no) Optimalisert uttrykking av HPV45-L1 i gjaer
NO20062674L (no) Optimalisert uttrykking av HPV58-L1 i gjaer
NZ589755A (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2011146933A3 (en) Universal dengue virus sequences and methods of use
WO2010040847A3 (en) Recombinant protein bodies as immunogen-specific adjuvants
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
MY138895A (en) Optimized expression of hpv 31 l1 in yeast
DE602005022458D1 (de) Impfstoff gegen humanes papillomavirus zur oralen verabreichung
WO2008153339A3 (en) A vaccine for treating or preventing pasteurellosis using a yeast surface-expression system
Guo et al. Development Status and trend of HPV vaccine
TH108752A (th) การแสดงที่ถูกทำให้เหมาะสมที่สุดของ hpv 52 l1 ในยีสต์
TH77200B (th) การแสดงที่ถูกทำให้เหมาะสมที่สุดของ hpv 52 l1 ในยีสต์
TH108752B (th) การแสดงที่ถูกทำให้เหมาะสมที่สุดของ hpv 52 l1 ในยีสต์
AR045249A1 (es) Expresion optimizada de hpv 31 l1 en levadura
TH64808B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv31 l1 ในยีสต์
TH82139B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: HPV 31 L1 PROTEIN; REG. NO/DATE: EU/1/15/1007/001-3 20150618

Spc suppl protection certif: 2018010

Filing date: 20180327

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: HPV 31 L1 PROTEIN; REG. NO/DATE: EU/1/15/1007/001-3 20150618

Spc suppl protection certif: 2018010

Filing date: 20180327

Extension date: 20290319

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP & DOHME LLC, US

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: HPV 31L1 PROTEIN - FORLENGET SPC; REG. NO/DATE: EU/1/15/1007/001-3 20150618

Spc suppl protection certif: 2022053

Filing date: 20221130